TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05067283: A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 830 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$6,942,936

Rescue Site Savings

+$4,586,736

Unlock Full NCT05067283 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05067283 Rescue Dossier →